Neogenomics Stock News

NeoGenomics (NASDAQ:NEO) had its target price reduced by Needham & Company LLC from $48.00 to $41.00 in a report issued on Tuesday morning, The Fly reports. They currently have a buy rating on the medical research company’s stock. Several other analysts also recently weighed in on the stock. Raymond James raised shares of NeoGenomics from […]

NeoGenomics (NASDAQ:NEO) had its target price dropped by research analysts at Needham & Company LLC from $48.00 to $41.00 in a report issued on Tuesday, The Fly reports. The firm currently has a buy rating on the medical research companys stock. Needham & Company LLCs price objective indicates a potential upside of 20.91% from the []

Within the last quarter, NeoGenomics (NASDAQ: NEO ) has observed the following analyst ratings:

Nisa Investment Advisors LLC trimmed its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 12.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 16,295 shares of the medical research companys stock after selling 2,393 shares during the quarter. Nisa Investment Advisors LLCs holdings in []

Related Stocks: NEO ,

NeoGenomics, Inc. (NASDAQ:NEO) has received an average rating of Buy from the eleven brokerages that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating on the company. The average 12-month price objective among brokers that have issued ratings on []

NeoGenomics, a company that moved to Gateway in 2006 with 1,200 square feet of space, has its new, Taj Mahal-esque headquarters. Its ready for all to see, including drivers heading north or south past Alico Road on Interstate 75 in south Lee County. The new address is 9490 NeoGenomics Way. The cancer diagnostics company partnered The post NeoGenomics new address appeared first on Gulfshore Business .

NeoGenomics, Inc. ''s stock price reached a new 52-week low on Monday after an insider sold shares in the company. The stock traded as low as $35.18 and last traded at $35.40

NeoGenomics, Inc. (NASDAQ:NEO)s stock price reached a new 52-week low on Monday after an insider sold shares in the company. The stock traded as low as $35.18 and last traded at $35.40, with a volume of 8173 shares traded. The stock had previously closed at $36.65. Specifically, insider Douglas Matthew Brown sold 33,334 shares of [] The post NeoGenomics (NASDAQ:NEO) Hits New 1-Year Low on Insider Selling appeared first on ETF Daily News .

Neogenomics Inc. (NEO) shares closed today at 1.1% above its 52 week low of $34.92, giving the company a market cap of $4B. The stock is currently down 34.4% year-to-date, down 25.5% over the past 12 months, and up 277.1% over the past five years. This week, the Dow Jones Industrial Average fell 1.4%, and the S&P 500 fell 0.6%. Trading Activity Trading volume this week was 43.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -216.4% The company's stock price performance over the past 12 months lags the peer average by -165.4% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 667.7% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

FT. MYERS, FL / ACCESSWIRE / November 30, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today

Millennium Management LLC cut its holdings in NeoGenomics, Inc. (NASDAQ:NEO) by 71.2% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 75,677 shares of the medical research companys stock after selling 187,059 shares during the period. Millennium Management LLCs holdings []